biosimilars - Robuta Search

https://biosimilarscouncil.org/ Home | Biosimilars Council | Leading Resource on Biosimilars Apr 2, 2026 - The Biosimilars Council, a division of the Association for Accessible Medicines, works to ensure a positive future for biosimilar medicines. biosimilars council leading resource https://www.goodwinlaw.com/en/news-and-events/news/2026/01/announcements-otherindustries-goodwin-releases-2025-26-update-to-annual Goodwin Releases 2025-26 Update to Annual Biosimilars Guide | News & Events | Goodwin goodwin releases update https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars Biosimilars | FDA FDA approved biosimilars are safe, effective treatment options. Biosimilars may provide more treatment options, increase access to lifesaving medications and... biosimilars fda https://www.indianpharmapost.com/biotech/biosimilars-performance-below-expectations-for-biocon-icici-direct-8443 Biosimilars performance below expectations for Biocon : ICICI Direct The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the... biosimilars performance expectations biocon icici https://www.iconplc.com/insights/therapeutics/biosimilars/making-sense-rapidly-changing-biosimilars-landscape Biosimilars market access biosimilars market access https://onpointanalytics.com/biosimilar-tracker/ Biosimilars Tracker - OnPoint Analytics Oct 13, 2020 - More than a decade after its enactment, the Biologics Price Competition and Innovation Act is finally transforming the economic and therapeutic landscape biosimilars tracker onpoint analytics https://www.fda.gov/regulatory-information/food-and-drug-administration-safety-and-innovation-act-fdasia/fact-sheet-new-biosimilars-user-fees-will-enhance-americans-access-alternatives-biologic-drugs Fact Sheet: New "Biosimilars" User Fees Will Enhance Americans' Access to Alternatives to Biologic... Fact sheet on provisions for user fees for review of biosimilar biologic drugs in the FDA Safety and Innovation Act https://www.hks.harvard.edu/publications/competition-age-biosimilars Competition in the Age of Biosimilars | Harvard Kennedy School In March 2015, the US Food and Drug Administration (FDA) approved the first biosimilar in the United States, ushering in the age of biosimilar competition for... in the competition age biosimilars harvard https://www.goodwinlaw.com/en/insights/blogs/2016/08/survey-suggests-pharmacists-prefer-non-proprietary-proper-names-for-biosimilars Survey Suggests Pharmacists Prefer Non-Proprietary Proper Names for Biosimilars | Insights &... proper names survey suggests pharmacists prefer https://www.biointron.com/antibody-industry-trends/week-4-september-2025-global-momentum-in-antibody-biosimilar.html Week 4, September 2025: Global Momentum in Antibody Biosimilars Monoclonal antibody (mAb) cost and accessibility challenges have fueled the development of biosimilars: biologic products designed to be copies of the... global momentum week september antibody biosimilars https://www.ukdailyledger.com/article/910780523-adalimumab-infliximab-etanercept-biosimilars-market-to-reach-8-04b-by-2030-at-10-1-cagr Adalimumab, Infliximab & Etanercept Biosimilars Market to reach $8.04B by 2030 at 10.1% CAGR | UK... UK Daily Ledger is an online news publication focusing on the United Kingdom: The most trusted news from the United Kingdom https://algaeforbiofuels.com/tag/biosimilars/ Biosimilars Archives - AlgaeForBiofuels biosimilars archives https://www.goodwinlaw.com/en/news-and-events/events/2023/11/practices-ip-biosimilars-patent-challenges-at-the-ptab Biosimilars Patent Challenges at the PTAB: Update and Lessons Learned | News & Events | Goodwin Biosimilars Patent Challenges at the PTAB: Update and Lessons Learned https://www.goodwinlaw.com/en/insights/blogs/2016/10/economic-times-of-india-report-suggests-that-indian-biosimilars-market-may-reach-40-billion-usd-by-2 Economic Times of India: Report Suggests that Indian Biosimilars Market May Reach $40 Billion USD... economic times of india https://myhealthcarereporter.com/article/910780523-adalimumab-infliximab-etanercept-biosimilars-market-to-reach-8-04b-by-2030-at-10-1-cagr Adalimumab, Infliximab & Etanercept Biosimilars Market to reach $8.04B by 2030 at 10.1% CAGR | My... https://biosim.care/ Biosimilars Care Navigator for Patients Navigate through this Web App to get essential information on the expanding landscape of biosimilars. In addition, the App provides useful resources for... care navigator biosimilars patients https://www.bccresearch.com/whitepapers/biosimilars-industry.html Biosimilars Industry Whitepaper: Karyo Biologics Interview Market Research Whitepaper from BCC Research Team: Innovation Spotlight Biosimilars industry. Exclusive interview with Professor Sarfaraz K. Niazi, a... industry whitepaper biosimilars biologics interview https://journalofbusinessnews.com/article/910780523-adalimumab-infliximab-etanercept-biosimilars-market-to-reach-8-04b-by-2030-at-10-1-cagr Adalimumab, Infliximab & Etanercept Biosimilars Market to reach $8.04B by 2030 at 10.1% CAGR |... https://www.thatsnice.com/thought-leadership/navigating-the-global-regulatory-landscape-for-biosimilars/ Navigating the Global Regulatory Landscape for Biosimilars - That's Nice | A Science Agency Nov 1, 2024 - Ensuring the safety, quality, and efficacy of biosimilars is essential to garnering confidence in these cost-saving medicines by physicians and patients. https://www.pilotforpulmonary.org/component/virtuemart/format/webinar/biosimilars-in-clinical-practice-interchangeability-and-extrapolation-detail Biosimilars in Clinical Practice: Interchangeability and Extrapolation As biosimilar guidance evolves in the United States and these biologics are studied and FDA-approved for use, it will be important for clinicians to understand... clinical practice biosimilars interchangeability extrapolation https://www.themarcomjournal.com/article/910780523-adalimumab-infliximab-etanercept-biosimilars-market-to-reach-8-04b-by-2030-at-10-1-cagr Adalimumab, Infliximab & Etanercept Biosimilars Market to reach $8.04B by 2030 at 10.1% CAGR | The... https://www.drugpatentwatch.com/p/biologics/established-pharmacologic-class/Skin+Test+Antigen When do biologic drug patents expire and when will biosimilars launch? When do drug patents expire? Pharmaceutical business intelligence, generic launch, global patents, and more biologic drug patents expire biosimilars https://streetchemx.com/product/koop-antibiotica-biosimilar-fermentoren/ Fermentoren voor Antibiotica & Biosimilars online Kopen voor antibiotica biosimilars online kopen https://www.cov.com/en/news-and-insights/insights/2017/01/biosimilars-in-italy-a-new-regime Biosimilars in Italy a new regime | Covington & Burling LLP in italy biosimilars new regime covington https://www.gabionline.net/reports/rheumatologists-are-prescribing-more-biosimilars Rheumatologists are prescribing more biosimilars Although the use of biosimilars for the treatment of autoimmune diseases varies widely by geographical region, the trend is that rheumatologists ar... rheumatologists prescribing biosimilars https://ukparliamentwatch.com/article/910780523-adalimumab-infliximab-etanercept-biosimilars-market-to-reach-8-04b-by-2030-at-10-1-cagr Adalimumab, Infliximab & Etanercept Biosimilars Market to reach $8.04B by 2030 at 10.1% CAGR | UK... https://mms.mckesson.com/content/insights/what-are-biosimilars-how-biosimilars-differ-from-biologics-in-cost-benefits/ What are biosimilars? How biosimilars differ from biologics in cost & benefits - McKesson... Jan 29, 2026 - There are multiple biosimilar products on the market today that help treat various disorders, including rheumatology, gastroenterology and ophthalmology... what are cost benefits biosimilars differ https://www.alliedacademies.org/abstract/eurobiosimilars-2019-interchangeability-of-biosimilars-and-intellectual-property-law--marek-swierczynski--university-of-cardinal-s-12691.html Eurobiosimilars 2019: Interchangeability of biosimilars and intellectual property law - Marek... Dynamic development of the market for biological medicines in recent years is strictly related to the expiration of the IP exclusive rights (in partic.. intellectual property law interchangeability biosimilars marek https://www.rapidnovor.com/t/biosimilars/ Biosimilars Archives - Rapid Novor biosimilars archives rapid https://www.cencora.com/resources/pharma/biosimilars-pipeline-report-for-understanding-the-growing-market Biosimilars pipeline report for understanding the growing market | Cencora Biosimilars are a promising product category, one that can provide patients and doctors with more affordable treatment options. pipeline report biosimilars understanding growing market https://grxbiosims.org/hotel/attachment/bethesda-north-marriott-3/ Bethesda-North-Marriott-3 - Generics + Biosimilars Conference bethesda north marriott generics biosimilars https://probiosimilars.de/glossar/?term=Wirtschaftlichkeitspr%C3%BCfung Glossar - AG Pro Biosimilars c/o Pro Generika e.V. Glossar Archive - AG Pro Biosimilars c/o Pro Generika e.V. glossar ag pro biosimilars c https://www.bigmoleculewatch.com/tag/biosimilars-news/ Biosimilars News Content tagged with Biosimilars News. biosimilars news https://www.uniprismmarketresearch.com/verticals/healthcare/biologics-and-biosimilars Biologics and Biosimilars Market Size, Share, Report Demand by 2033 The Biologics and Biosimilars Market research report analyzes trends, key players, and growth drivers, offering insights into market dynamics and future... biologics and biosimilars market size share report demand https://grxbiosims.org/learning-track/biosimilars-at-a-crossroads-utilization-management-and-the-path-to-sustainable-access/ Biosimilars at a Crossroads: Utilization Management and the Path to Sustainable Access - Generics +... at a crossroads https://www.raps.org/resource/ema-shares-lessons-learned-from-biosimilars-pilot.html EMA shares lessons learned from biosimilars pilot | RAPS The lack of mature quality data, such as sufficient batch data, hindered the ability of the European Medicines Agency (EMA) to provide scientific advice to... lessons learned ema shares biosimilars pilot https://research.ajman.ac.ae/en/publications/utilisation-trend-of-long-acting-insulin-analogues-including-bios/ Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings... https://www.woodleybioreg.com/biosimilars-development-successful-scientific-advice-to-accelerate-development-and-registration/ Biosimilars development: Successful scientific advice to accelerate development and registration -... Jun 23, 2023 - Woodley BioReg delivered successful scientific advice to accelerate biosimilars development and the registration of a biological product. scientific advice biosimilars development successful accelerate https://www.gaudio.co.uk/trophy/global-generics-biosimilars-award/ Discover Our Custom Global Generics & Biosimilars Award Trophy | Gaudio discover our global generics award trophy custom biosimilars https://biosimsforum.com/chow-260/ Chow-260 | Biosimilars Forum chow biosimilars forum https://www.expresspharma.in/dr-reddys-lines-up-rs-1500-crore-capex-to-focus-on-biosimilars-and-injectables/ Dr Reddy's lines up Rs 1,500 crore capex to focus on biosimilars and injectables - Express Pharma https://www.biosimilarsip.com/tag/pegfilgrastim/ pegfilgrastim | Biosimilars Law Bulletin | Rothwell Figg biosimilars law bulletin rothwell figg https://www.biosimilarsip.com/ Biosimilars Law Bulletin | Rothwell Figg | Biologics and Biosimilars Practice Authored and edited by Rothwell Figg attorneys, Biosimilars Law Bulletin provides updates and analysis about regulatory issues, legal decisions and other news... biosimilars law bulletin rothwell figg biologics practice https://www.biosimilarsip.com/category/regulatory/ Regulatory | Biosimilars Law Bulletin | Rothwell Figg BiosimilarsIP.com Regulatory provides articles about regulatory issues and events related to biologics and biosimilars from the FDA, the EMA and other... biosimilars law bulletin regulatory rothwell figg https://tanyaleeherveyphotography.com/addressing-patient-concerns-about-biosimilars-reducing-hesitation-and-building-trust Addressing Patient Concerns About Biosimilars: Reducing Hesitation and Building Trust Biosimilars offer major cost savings and proven safety, but patient hesitation persists due to misinformation and lack of communication. Learn how to address... patient concerns about biosimilars addressing reducing hesitation https://www.govinfo.gov/app/details/BILLS-119s1414is S. 1414 (IS) - Expedited Access to Biosimilars Act - BILLS-119s1414is | Content Details | GovInfo https://www.medicinesforeurope.com/2016/11/22/qa-for-patients-biosimilar-medicines-explained/patient-qa-on-biosimilars-july-2016-final/ patient-qa-on-biosimilars-july-2016-final | Medicines for Europe patient qa biosimilars july final medicines https://repository.innoskills.com/items/4437cf0a-0cd3-46a0-95a1-0018a430333a Adoption and Manufacturing of Biosimilars for Autoimmune Diseases in Jordan and the Middle East:... Biologic medicines have transformed the treatment of autoimmune and chronic diseases, but their development is highly complex, time-consuming, and costly.... https://www.emjreviews.com/oncology/video/biosimilars-for-breast-cancer-treatment/ Biosimilars for breast cancer treatment - European Medical Journal Apr 24, 2015 - At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Peter Schmid (Barts Cancer Institute, London, UK) discusses the key challenges... breast cancer treatment biosimilars european medical journal https://www.sandoz.ca/global-biosimilars-week/ Global Biosimilars Week | Sandoz Canda global biosimilars week sandoz canda https://www.frenchguianapress.com/article/910780523-adalimumab-infliximab-etanercept-biosimilars-market-to-reach-8-04b-by-2030-at-10-1-cagr Adalimumab, Infliximab & Etanercept Biosimilars Market to reach $8.04B by 2030 at 10.1% CAGR |... French Guiana Press is an online news publication focusing on the French Guiana: The latest news from French Guiana https://www.gabionline.net/layout/set/print/biosimilars/news/Market-protection-for-biologicals-should-be-less-than-12-years Market protection for biologicals should be less than 12 years / News / Biosimilars / Home - GaBi... Content Management System https://www.prnewswire.co.uk/news-releases/biosimilars-market-size-to-hit-76-2-billion-by-2030---driving-value-based-care-for-drugmakers-regulators--emerging-markets--the-research-insights-302495544.html Biosimilars Market Size to Hit $76.2 Billion by 2030 - Driving Value-Based Care for Drugmakers,... /PRNewswire/ -- What's Fuelling the US$76.2 Billion Biosimilars Market? The Global Biosimilars Market size is projected to be valued at USD 27.20 billion in... https://www.prnewswire.co.uk/news-releases/japan-pharma-outlook-2015-year-to-watch-out-for-authorized-generics-ags-biosimilars-and-overseas-strategic-initiatives-295146931.html Japan Pharma Outlook 2015: Year to Watch out for Authorized Generics (AGs), Biosimilars and... /PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/gl7m98/japan_pharma) has announced the addition of the "Japan Pharma Outlook... https://www.dcatvci.org/top-industry-news/merck-samsung-advance-biosimilars/ Merck, Samsung Advance Biosimilars - DCAT Value Chain Insights value chain merck samsung advance biosimilars https://www.consultantlive.com/view/the-safety-and-efficacy-of-adalimumab-biosimilars-in-inflammatory-diseases The Safety and Efficacy of Adalimumab Biosimilars in Inflammatory Diseases Specialists in rheumatology, dermatology and gastrointestinal disease discuss clinical trials that have shown safety and efficacy of adalimumab biosimilars in... safety and efficacy adalimumab biosimilars inflammatory diseases https://gabionline.net/policies-legislation/Australia-encouraging-biosimilars-and-mandating-drug-shortage-reporting Australia encouraging biosimilars and mandating drug shortage reporting In an effort to address both the rising prices of medicines and the risk of drug shortages in Australia the country has introduced drivers to encou... australia encouraging biosimilars drug shortage https://biosimsforum.com/ina-christina-video/ Ina-Christina-video | Biosimilars Forum ina video biosimilars forum https://biosimsforum.com/2017/06/16/responsive-wordpress-theme/ Responsive WordPress Theme - Biosimilars Forum Jun 16, 2017 - Cras justo odio, dapibus ac facilisis in, egestas eget quam. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean lacinia bibendum nulla sed... responsive wordpress theme biosimilars forum https://biosimilarsforum.org/resource/ Resources Archive - Biosimilars Forum resources archive biosimilars forum https://www.cas.org/es-es/cas-events/biosimilars-latam-2026 Biosimilars LatAm 2026 | CAS Events biosimilars latam cas events https://www.gabionline.net/layout/set/print/biosimilars/(offset)/2230/(limit)/10 Biosimilars / Home - GaBi Online | Global Content Management System biosimilars gabi online global https://biosimsforum.com/ 3rd Annual Biosimilars Forum - 2018 Nov 2, 2021 - World’s prominent biosimilar development experts will return to Budapest on October 25 – 26th, 2018 to the 3rd Annual Biosimilars Forum. annual biosimilars forum https://www.acrconvergencetoday.org/biosimilars-offer-therapeutic-management-options-but-come-with-challenges-regarding-safety-efficacy/ Biosimilars offer therapeutic management options, but come with challenges regarding safety,... Aug 24, 2017 - Candida Fratazzi, MD, the president of BBCR Consulting in Cambridge, Massachusetts, who will speak during Emerging Biosimilars in Therapeutic Management: Where... management options biosimilars offer therapeutic https://www.goodwinlaw.com/en/insights/blogs/2021/05/bipartisan-legislation-introduced-to-increase-access-to-biosimilars-in-medicare-plans Bipartisan Legislation Introduced to Increase Access to Biosimilars in Medicare Plans | Insights &... increase access medicare plans bipartisan legislation introduced https://lawfina.com/regulation-of-biologics-and-biosimilars/ Regulatory Frameworks for biologics and biosimilars: An In-Depth Analysis - Lawfina Oct 1, 2024 - Explore the regulation of biologics and biosimilars within Food and Drug Law, covering approval processes, legal considerations, and market entry requirements. biologics and biosimilars regulatory frameworks in depth https://biosimsforum.com/locked-icon-50/ locked-icon-50 | Biosimilars Forum locked icon biosimilars forum https://www.ispor.org/vih-articles/Volume-16--Issue-7/Price-Differences-Triggered-by-the-Availability-of-Biosimilars-in-Developed-Countries Price Differences Triggered by the Availability of Biosimilars in Developed Countries by the price differences triggered https://biosimsforum.com/20171005_120434_w/ 20171005_120434_w | Biosimilars Forum w biosimilars forum https://www.digitalhealthnews.com/amneal-to-acquire-kashiv-biosciences-to-expand-global-biosimilars-platform Amneal to acquire Kashiv BioSciences in biosimilars expansion move Amneal Pharmaceuticals will acquire Kashiv BioSciences to build a fully integrated biosimilars platform, with the deal expected to close in the second half of... kashiv biosciences amneal acquire biosimilars expansion https://www.fideres.com/pay-to-delay-biosimilars-and-the-cost-of-competition/ Pay-to-Delay: Biosimilars And The Cost Of Competition - Fideres Apr 27, 2026 - Analysis of pay-to-delay scrutiny in biosimilar markets where drugs sell at fractions of biologic prices. and the pay delay biosimilars cost https://familymeds.su/clinical-outcomes-with-biosimilars-do-they-work-as-well-as-the-original-biologics Clinical Outcomes with Biosimilars: Do They Work as Well as the Original Biologics? Biosimilars work just as well as original biologic drugs, with proven safety and effectiveness across hundreds of studies. Learn how they're regulated, why... clinical outcomes they work https://www.vivo-science.com/our-offers/immunoefficacy/ GLP Safety and Efficacy of Biosimilars and Small Molecules | vivo Science GmbH vivo Science has implemented a broad spectrum of human and rodent-based in vitro and in vivo models for the assessment of immune efficacy. safety and efficacy small molecules glp https://gabionline.net/biosimilars/research/Expediting-FDA-approvals-for-biosimilars Expediting FDA approvals for biosimilars A number of recommendations for the US Food and Drug Administration (FDA) to simplify biosimilar licensing laws, and thus make biosimilars more acc... fda approvals expediting biosimilars https://www.ispor.org/vih-articles/Volume-23--Supplemental-S2/PBI37-Infliximab-and-Etanercept-Biosimilars-and-Originators--Learnings-from-Regional-Market-Dynamics-in-Germany PBI37 Infliximab and Etanercept Biosimilars and Originators: Learnings from Regional Market... infliximab etanercept biosimilars originators learnings https://www.goodwinlaw.com/en/insights/blogs/2025/04/accord-receives-positive-ema-opinion-for-two-denosumab-biosimilars Accord Receives Positive EMA Opinion for Two Denosumab Biosimilars | Insights & Resources | Goodwin for two https://www.gabionline.net/guidelines/US-guidelines-for-biosimilars US guidelines for biosimilars Last update: 25 October 2019The regulatory body for approval of medicines in the US is the Food and Drug Administration (FDA). us guidelines biosimilars https://probiosimilars.de/glossar/?term=Biopharmazeutika Glossar - AG Pro Biosimilars c/o Pro Generika e.V. Glossar Archive - AG Pro Biosimilars c/o Pro Generika e.V. glossar ag pro biosimilars c https://www.amadaamiga.com/group/amada-amiga-group/discussion/24c314e6-4e91-4925-8497-e168bbf78005 The Impact of Biosimilars and Generics The Baricitinib Mark | amada amiga support | amada amiga Aug 29, 2025 - The Impact of Biosimilars and Generics The Baricitinib Market is a rapidly expanding segment of the global pharmaceutical industry, driven by the drug's... the impact biosimilars https://pharmaphorum.com/news/cheaper-soliris-biosimilars-reach-us-market Cheaper Soliris biosimilars reach the US market | pharmaphorum The first biosimilars of AstraZeneca/Alexion's blockbuster complement C5 inhibitor Soliris have been launched in the US at a discount to the brand the us cheaper biosimilars reach market https://www.bigmoleculewatch.com/tag/biosimilars-summit/ Biosimilars Summit Content tagged with Biosimilars Summit. biosimilars summit https://e-fama.gedeonrichter.pt/the-future-of-biosimilars/ The Future of Biosimilars - FAMA - Gedeon Richter Portugal the future of gedeon richter biosimilars fama portugal https://www.bioprocessonline.com/doc/can-biosimilars-be-the-bridge-to-more-widespread-continuous-bioprocessing-0001 Can Biosimilars Be The Bridge To More Widespread Continuous Bioprocessing This article will examine the relationship between improved continuous manufacturing (CM) and biosimilar development, paying particular attention to the... be the bridge biosimilars widespread continuous bioprocessing https://www.mmrstatistics.com/statistics/184392/mea-biosimilars-market-share-country-2025 MEA Biosimilars Market Share, by Country (2025) | MMR Statistics Nov 27, 2025 - Discover MEA Biosimilars Market; GCC leads with 39.28% in 2025, expected to dominate through 2032 due to high healthcare investment and biologics access. market share by country mea biosimilars mmr https://mwbconsulting.com/biologics-and-biosimilars/ Biologics and Biosimilars Compliance Services biologics and biosimilars compliance services https://expressy.co.in/u-s-and-global-oncology-biosimilars-market-outlook-to-2031-growth-key-players-and-future-trends/ U.S. and Global Oncology Biosimilars Market Outlook to 2031: Growth, Key Players, and Future Trends... Apr 23, 2026 - The Oncology Biosimilars Market is witnessing rapid expansion as healthcare systems across the globe seek cost-effective alternatives to expensive biologic... https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/alkem-labs-to-grow-chronic-therapies-biosimilars-to-drive-future-growth-md/articleshow/100782771.cms alkem: Alkem Labs to grow chronic therapies, biosimilars to drive future growth: MD - The Economic... Alkem Laboratories, a top-seller of antibiotics, is focusing on the chronic therapy segments and is investing heavily in biosimilars and contract development... https://gabionline.net/reports/us-savings-from-biosimilars-could-exceed-us-100-billion US savings from biosimilars could exceed US$100 billion At the AAM 2021 Annual Meeting, Mr Doug Long* of IQVIA delivered a presentation on US biosimilar market access, indicating savings over the next fi... us savings biosimilars could exceed billion https://www.americanbusinesstimes.com/article/910780523-adalimumab-infliximab-etanercept-biosimilars-market-to-reach-8-04b-by-2030-at-10-1-cagr Adalimumab, Infliximab & Etanercept Biosimilars Market to reach $8.04B by 2030 at 10.1% CAGR |... https://digestivecancers.eu/turning-potential-into-action-how-biosimilars-can-reshape-access-and-outcomes-in-cancer-care/ Turning Potential into Action: How Biosimilars Can Reshape Access and Outcomes in Cancer Care -... Apr 28, 2025 - At BIOS25 in Amsterdam, DiCE highlighted patient perspectives on biosimilars. CEO Zorana Maravic underscored the urgent need to overcome barriers, ensuring... https://www.bigmoleculewatch.com/2025/09/04/fda-approves-denosumab-biosimilars-bildyos-and-bilprevda/ FDA Approves Denosumab Biosimilars BILDYOS and BILPREVDA - Big Molecule Watch On September 2, 2025, Shanghai Henlius Biotech, Inc. and Organon announced that the FDA has approved BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp)... fda denosumab biosimilars big molecule https://www.bioconbiologics.com/about-us/our-work-in-biosimilars/ Our work in Biosimilars - Biocon Biologics Jun 20, 2025 - Biocon Biologics has one of the largest global biosimilars portfolios spanning recombinant human Insulin (rh-Insulin), insulin analogs... our work biosimilars biocon biologics https://www.healthhub.sg/medication-devices-and-treatment/medications/biologics-and-biosimilars Biologics and Biosimilars Medication Information Leaflet biologics biosimilars https://www.goodwinlaw.com/en/insights/blogs/2016/10/push-to-lower-prescription-drug-prices-could-have-an-effect-on-biosimilars-market Push to Lower Prescription Drug Prices Could Have an Effect on Biosimilars Market | Insights &... https://bioconbiologicseu.com/fi/transparency/ Biocon Biologics | Advancing Biosimilars for a Healthier and Affordable Future Dec 2, 2025 - Biocon Biologics is a leading global player in the development, manufacturing and commercialization of biosimilars. Our cutting-edge science, extensive... biocon biologics for a advancing biosimilars healthier https://wtguru.com/news/biosimilars Biosimilars News | WTGuru Read latest Biosimilars updates curated by WTGuru. biosimilars news https://pr.euractiv.com/?q=pr/pan-european-survey-calls-shift-policy-biosimilars-105149 Pan-European survey calls for a shift in policy for biosimilars | EURACTIV PR Today, the Alliance for Safe Biologic Medicines (ASBM) disclosed the results of a survey of 470 European physicians, that took place in Q3 of 2013, across five... calls for https://www.marketsandmarkets.com/biosimilars-market-research-37.html Biosimilars Market Research Reports & Consulting from MarketsandMarkets Find Biosimilars market research reports and Biosimilars industry analysis including industry overviews, market segmentation data, market share and growth. market research reports biosimilars consulting marketsandmarkets https://www.propharmagroup.com/thought-leadership/fda-new-guidance-biosimilars FDA Releases New Guidance on Meetings with Sponsors of Biosimilars Get an in-depth breakdown of how the March 2013 draft guidance for sponsors of biosimilar products changes the previous framework through new updates. new guidance fda releases meetings sponsors https://www.cov.com/en/news-and-insights/insights/2017/09/advertising-and-promotion-of-biological-products-including-biosimilars Advertising and Promotion of Biological Products Including Biosimilars | Covington & Burling LLP advertising and promotion biological products